Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0009676 (confusion)
 21,692 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We describe the case of a 55-year-old woman with metastatic colorectal cancer, treated with bevacizumab, who developed sudden occipital pain, with nausea, vomiting, mild confusion, and signs of meningeal irritation. Imaging studies (computed tomographic scan and magnetic resonance imaging) revealed a pretruncal subarachnoid hemorrhage without an underlying vascular malformation; transcranial Doppler carried out 24 hours after the clinical onset showed increased blood flow velocities, mainly in the right middle cerebral artery. The neurological and hemodynamic alterations resolved with medical treatment within 10 days. Bevacizumab is a humanized monoclonal antibody that inhibits the vascular endothelial growth factor. The potential role of anti-vascular endothelial growth factor treatment on the subarachnoid hemorrhage and increased cerebral blood flow velocities is discussed.
 ...
PMID:Pretruncal subarachnoid hemorrhage and high cerebral blood flow velocities with bevacizumab therapy. 2086 39

On November 18, 2011, the US Food and Drug Administration (US FDA) announced that breast cancer indication for Avastin (bevacizumab) had been withdrawn after concluding that the drug has not been shown to be safe and effective for the treatment of breast cancer. The specific indication that was withdrawn was for the use of bevacizumab in metastatic breast cancer, with paclitaxel for the treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer. The US FDAs decision has been met with emotion and confusion among the public and health professionals. The purpose of this article is to review the regulatory history of bevacizumab for breast cancer and to examine the scientific evidence that led to the approval and subsequent withdrawal of this indication. Bevacizumab also provides the opportunity to illustrate the value of free publicly available US FDA reviews that may contain rigorously reviewed unpublished data and analyses and to contrast the decisions made in the US and Europe about bevacizumab and breast cancer.
...
PMID:The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). 2396 Aug 13

Posterior reversible leukoencephalopathy syndrome (PRES) is a syndrome characterized by headache, hypertension, confusion, visual disturbance, and seizures accompanied by subcortical vasogenic edema, predominantly involving the parietal and occipital lobes. The syndrome is usually described in malignant hypertension, eclampsia, renal failure, immunosuppressive, and cytotoxic chemotherapies. Bevacizumab, a monoclonal antibody that binds to the vascular endothelial growth factor (VEGF) has been linked to PRES. We carried out review of reports documenting the occurrence of PRES in patients receiving bevacizumab. This literature review was conducted by utilizing PubMed Database. If early diagnosed, PRES is reversible. We present a case of fatal PRES-associated coma induced by bevacizumab in metastatic colorectal cancer.
 ...
PMID:Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. 2646 67